Abstract
Background Delay to cancer diagnosis is associated with poorer outcomes. In response to delays to cancer diagnosis in the UK, a number of Rapid Diagnosis Centres (RDCs), Multi-Disciplinary Centres (MDCs) and other pathway reforms have been piloted and implemented in recent years. Prostate cancer is the most commonly diagnosed cancer for men or those assigned male at birth in the UK. In Wales, the recommended time to diagnosis is within 62 days from point of suspicion. For patients served by Hywel Dda University Health Board, current waiting times on the prostate cancer diagnostic pathway are prolonged, falling well outside the 28-day decision to treat and 62-day referral to treatment targets. A revised prostate cancer diagnostic pathway called Prostad (Wesh for “prostate”) has been developed and is currently being implemented with the aim of reducing time to diagnosis (or discharge) for patients referred for investigation. This protocol describes Prostad and the planned evaluation approach.
Methods This is a mixed-method evaluation. It is shaped by patient and public involvement throughout and incorporates realist interviews with multiple stakeholders (including NHS staff and patients), process mapping, economic evaluation, and monitoring of the intervention against its aims using routinely collected data.
Discussion To the authors’ knowledge, this is the first project of its kind to combine service aims evaluation, cost-effectiveness analysis and realist evaluation approaches, and as such promises findings applicable to organisations and individuals with regard to various aims and priorities. Continued patient and public involvement throughout the study constitutes one of its strengths.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The evaluation has been approved by the Research, Innovation and Value Based Health Care Department at Hywel Dda University Health Board NHS research ethics approval was not required for this health board-led evaluation. Swansea University Ethics Committee granted its favourable opinion on 9th January 2024.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.
